TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form of brain cancer. A therapy candidate is named to the fast track program if it might treat serious conditions with unmet clinical need, either because no treatments are currently available or because the potential treatment offers significant benefits over approved alternatives. This designation is meant to…
You must be logged in to read/download the full post.
The post Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track appeared first on BioNewsFeeds.